



Innovation From Within™

## **Kineta Announces Collaboration, Receives Funding and Investments for Multiple Programs**

*Company also Named in Biotech Top Ten List*

SEATTLE, WA, Oct., 27, 2009 – Kineta, Inc. made several announcements today surrounding both its lead autoimmune program and antiviral discovery program. President and CEO, Charles L. Magness, Ph.D., said the company has entered into a strategic alliance with MPI Research of Mattawan, Michigan.

MPI Research will provide preclinical studies and investments to advance Kineta's autoimmune program. The studies enable phase one human trials to commence in 2010.

Dr. Magness also announced The National Institute of Allergy and Infectious Disease, part of the National Institutes of Health, awarded second year funding to Kineta on a phase one Small Business Innovation Research (SBIR) grant for the company's novel discovery stage antiviral research program. The two year, total \$585,000 grant is funding Kineta's early stage research on agonists of the Retinoic Acid Inducible Gene I (RIG-I) Pathway.

"This is substantial validation of Kineta's novel research target, and more, high level acknowledgement of the need for better antiviral drugs. Kineta is in a unique position to deliver next generation drugs for influenza and many other deadly viruses," said Shawn P. Iadonato, Ph.D., Kineta's Executive Vice President and Chief Scientific Officer.

In August, Kineta was recognized as one of the nation's top ten most promising biotechnology companies by leading industry publication, *Pharmaceutical Executive*. The article cites the experienced Kineta executive team, novel scientific programs and investor focused business model as contributors to the company's "ingenuity."

For more information on today's announcements or to schedule interviews contact Meg O'Connor, [moconor@kinetabio.com](mailto:moconor@kinetabio.com) 206-251- 8638

#####

**Kineta, Inc.** is a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system. Our world class scientists are pioneers, developing life-changing classes of drugs that harness the power of the immune system to fight disease. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases. Our progressive business model focuses on targeting unmet medical needs and on rapid achievement of important clinical milestones. Through careful management of capital, Kineta aims at a strong return for investors. For more information on Kineta Inc. visit our website, [www.Kinetabio.com](http://www.Kinetabio.com)

The project described is supported by Award Number R43AI081335 from the National Institute of Allergy And Infectious Diseases. The content is solely the responsibility of the authors and does not

necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institutes of Health.

This press release contains forward-looking statements, including without limitation, all statements related to plans, future events and financial performance. Forward-looking statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. The companies' actual results and timing of events could differ materially, including efficacy and demand for our products, our ability to manage our costs, competition from other drug development companies, and our ability to recruit and maintain senior management and other key personnel. The companies' stakeholders are cautioned not to place undue reliance on these forward-looking statements, which reflect only an analysis and speak only as of the date of this press release. The companies undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.